Residual and Recurrent Gastrointestinal Stromal Tumors With KIT Mutations: Findings at First Follow-Up CT After Imatinib Treatment
July 23rd, 2009 Posted by: admin
OBJECTIVE. The purpose of this study was to correlate findings on
the first follow-up CT after treatment with imatinib in patients with residual
or recurrent gastrointestinal stromal tumors (GISTs) with the different types
of KIT mutation present at initial resection.
CONCLUSION. Residual and recurrent GISTs with KIT mutation
of exon 11 deletion more frequently showed both tumor shrinkage and cystic
change on 2-month follow-up CT images after the start of imatinib treatment
than did other mutation types.
